FindTrial
Sign In

Meropenem and Pralurbactam

DRUG3 trials

Sponsors

Qilu Pharmaceutical Co., Ltd.

Conditions

Bloodstream Infection (BSI)Complicated Intra-abdominal Infection (cIAI)Complicated Urinary Tract Infection (cUTI)Hospital-acquired Bacterial Pneumonia (HABP)Hospital-acquired Bacterial Pneumonia and Ventilator-associated Bacterial PneumoniaIntra-abdominal InfectionsVentilator-associated Bacterial Pneumonia (VABP)

Phase 3

Study to Assess the Efficacy and Safety of Meropenem and Pralurbactam in CIAI
Not yet recruitingNCT06633718
Qilu Pharmaceutical Co., Ltd.Intra-abdominal Infections
Start: 2024-10-31End: 2027-05-30Target: 786Updated: 2024-10-09
Study to Assess the Efficacy and Safety of Meropenem and Pralurbactam in Carbapenem-Resistant Enterobacteriaceae Infections
RecruitingNCT07089186
Qilu Pharmaceutical Co., Ltd.Bloodstream Infection (BSI), Complicated Intra-abdominal Infection (cIAI), Complicated Urinary Tract Infection (cUTI) +2
Start: 2025-04-12End: 2027-04-30Target: 80Updated: 2025-07-30
A Study to Evaluate the Efficacy and Safety of Meropenem and Pralurbactam in HABP/VABP
RecruitingNCT07327619
Qilu Pharmaceutical Co., Ltd.Hospital-acquired Bacterial Pneumonia and Ventilator-associated Bacterial Pneumonia
Start: 2026-01-22End: 2028-10-01Target: 420Updated: 2026-02-17